|Budget Amount *help
¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
Fiscal Year 2013: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2012: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2011: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Toward developing a therapy for the polyglutamine (polyQ) neurodegenerative diseases by specific degradation of expanded polyQ proteins, 1) we showed that p62 plays an important role in the autophagic clearance of polyQ protein, especially its oligomers, resulting in protection against polyQ-induced neurodegeneration in Drosophila. 2) We further designed the p62-QBP1 chimeric protein, which consists of p62, an adaptor protein for selective autophagy and the expanded polyQ-specific binding peptide QBP1, and demonstrated its therapeutic potential for the polyQ diseases by selective degradation of expanded polyQ proteins.